natgillin/translations-raw huggingface dataset:
Interferon beta 1-a is a form of a protein that is naturally produced by the body.
Beeta-1a interferoon on organismi poolt looduslikult toodetava valgu vorm.
Interferon beta- 1a, 30 μg
Beeta-1a- interferoon, 30 μg
Interferon beta-1a
Beeta-1a-interferoon
Interferon beta-1a (intramuscular) 30 micrograms
30 mikrogrammi (intramuskulaarset) beeta-1a interferooni
Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.
Beeta-1a-interferoon metaboliseeritakse ja eritatakse peamiselt maksa ja neerude kaudu.
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce interferon beta-1a.
Beeta-1a-interferooni valmistatakse rekombinant-DNA-tehnika abil: seda toodavad rakud, millesse on viidud beeta-1a-interferooni teket võimaldav geen (DNA).
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: the interferon beta-1a is made by a cell that has received a gene (DNA), which makes it able to produce it.
Beeta-1a-interferooni valmistatakse rekombinant-DNA-tehnika abil: ravimit toodab rakk, millele on lisatud beeta-1a-interferooni teket võimaldav geen (DNA).
Interferon beta-1a SC use
Beeta-1a-interferoon Subkutaanne
Interferon beta-1b has been given to adult cancer patients at individual doses as high as
Beeta-1b interferooni on manustatud täiskasvanud vähihaigetele intravenoosselt annuses
Interferon beta-1b is produced by a method known as ‘recombinant DNA technology’.
Beeta-1b-interferooni valmistatakse rekombinant-DNA-tehnika abil.
Interferon classification
Interferooni klassifikatsioon
Interferon may impair fertility (see section 4.6 and section 5.3).
Interferoon võib mõjutada viljakust (vt lõik 4.6 ja 5.3).
Interferon monotherapy, including PegIntron, is indicated mainly in case of intolerance or contraindication to ribavirin.
Monoteraapia interferooni, sh PegIntron’iga, on näidustatud peamiselt ribaviriini talumatuse või vastunäidustuse puhul.
Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or contraindication to ribavirin.
Monoteraapia interferooni, sh ViraferonPeg’iga, on näidustatud peamiselt ribaviriini talumatuse või vastunäidustuse puhul.
Interferon neutralising factor assays were performed on serum samples of patients who received IntronA in Schering-Plough monitored clinical trials.
Schering-Plough’ poolt jälgitavas kliinilises uuringus osalevate IntronA patsientide seerumiproove kasutades viidi läbi ka interferooni neutraliseeriva faktori määramine.
Interferon neutralising factor assays were performed on serum samples of patients who received PegIntron in the clinical trial.
Kliiniliste uuringute käigus PegIntron’i saanud patsientide seerumiproove testiti ka interferooni neutraliseerivate faktorite suhtes.
Interferon neutralising factor assays were performed on serum samples of patients who received ViraferonPeg in the clinical trial.
Kliiniliste uuringute käigus ViraferonPeg’i saanud patsientide seerumiproove testiti ka interferooni neutraliseerivate faktorite suhtes.
interferon, to treat viral infections
interferoon, mida kasutatakse viirusnakkuste raviks
interferon, to treat viral infections
interferoon, viirusinfektsioonide raviks
Interferon: fampridine has been administered concomitantly with interferon-beta and no pharmacokinetic medicinal product interactions were observed.
Interferoon: fampridiini on manustatud samaaegselt koos beetainterferooniga ja mingeid farmakokineetilisi koostoimeid ei täheldatud.
Interferons alpha and beta are classified as Type I interferons and interferon gamma is a Type II interferon.
Interferoonid alfa ja beeta klassifitseeritakse kui I tüübi interferoonid ja interferoon gamma kui II tüübi interferoon.
Interferons and Nevirapine Teva may be co-administered without dose adjustments.
Interferoone ja Nevirapine Teva’t tohib ilma annust kohandamata samaaegselt kasutada.
Interferons and Viramune may be coadministered without dose adjustments.
Interferoone ja Viramune’i tohib ilma annust kohandamata samaaegselt kasutada.
Interferons are a family of naturally occurring proteins that are induced by cells in response to biological and chemical stimuli, and mediate numerous cellular responses that have been classified as antiviral, antiproliferative, and immunomodulatory in nature.
Interferoonid on looduslike valkude rühm, mida toodetakse rakkudes vastusena bioloogilistele ja keemilistele mõjutustele ning mis vahendavad mitmesuguseid antiviiruslikke, antiproliferatiivseid ja immunomoduleerivaid rakkude toimeid.
Interferons are a family of naturally occurring proteins that are induced by cells in response to biological and chemical stimuli, and mediate numerous cellular responses that have been classified as antiviral, antiproliferative, and immunomodulatory in nature.
Interferoonid on looduslike valkude rühm, mida toodetakse rakkudes vastusena bioloogilistele ja keemilistele mõjutustele ning mis vahendavad mitmesuguseid antiviiruslikke, antiproliferatiivseid ja immuunmoduleerivaid rakkude toimeid.
Interferons are cytokines that mediate antiviral, antiproliferative and immunomodulatory activities.
Interferoonid on antiviraalset, antiproliferatiivset ja immuunmoduleerivat toimet vahendavad tsütokiinid.
Interferons are made by your body’s immune system to help fight infections and severe diseases.
Interferoone toodab teie keha immuunsüsteem, võitlemaks infektsioonide ja raskete haiguste vastu.
Interferons belong to the family of cytokines, which are naturally occurring proteins.
Interferoonid kuuluvad tsütokiinide – looduslike proteiinide perekonda.
interferons taken with or without ribavirin – used to treat hepatitis.
interferoonid koos ribaviriiniga või ilma – kasutatakse hepatiidi raviks;
Interim
32,1)
Interim
Vahepealne
Interim analyses reports provided annually beginning Q4 2015 until completion of the study program.
Vaheanalüüsi raportid esitatakse igal aastal alates 2015 aasta IV kvartalist kuni uuringuprogrammi lõppemiseni.
Interim analysis
1. vaheanalüüs:
Interim analysis
detsember 2019
Interim analysis of results (as of May 2015) from the ongoing TYSABRI Observational Program (TOP), a phase 4, multicentre, single-arm study (n=5770) demonstrated that patients switching from beta interferon (n= 3255) or glatiramer acetate (n= 1384) to TYSABRI showed a sustained, significant decrease in annualised relapse rate (p< 0.0001).
Käimasoleva TYSABRI vaatlusprogrammi (TYSABRI Observational Program, TOP), IV faasi mitmekeskuselise ühe ravirühmaga uuringu (n = 5770) tulemuste vaheanalüüs (2015. aasta mai seisuga) näitas, et beeta-interferoonilt (n = 3255) või glatirameeratsetaadilt (n = 1384) TYSABRI’le üleviidud patsientidel vähenes püsivalt ja olulisel määral ägenemiste esinemissagedus aastas (p < 0,0001).
Interim data from an ongoing study of cardiovascular outcomes were reviewed during the assessment although the CHMP also recommended ongoing monitoring of the medicine’s cardiovascular effects.
Hindamises vaadati läbi käimasoleva kardiovaskulaarsete tulemuste uuringu vaheandmed, kuid inimravimite komitee soovitas siiski ravimi kardiovaskulaarset toimet järjepidevalt seirata.
Interim IDMC analysis when half of the patients reach W76: 2Q 2018
IDMC vaheanalüüs, kui pooled patsientidest on jõudnud 76. nädalani: 2Q 2018
Interim OS (52% maturity)
Esialgne ÜE (52% küpsus)
Interim OS analysis conducted at 40% of total events required for final analysis.
OS-i vaheanalüüs hõlmas 40% lõppanalüüsi jaoks vajalikust juhtude koguarvust.
Interim reports should be provided at the time of annual re- assessments.
Vahearuanded tuleb esitada iga-aastaste kordushindamiste ajal.
Interim reports submitted yearly in the frame of the Annual Re-assessment
Vahearuanded esitatakse üks kord aastas iga-aastase korduseksper- tiisi raames
Interim results showed an increased risk of mortality and serious adverse events in subjects receiving riociguat compared to those receiving placebo.
Uuringu vaheanalüüsi tulemused näitasid riotsiguaati saanud patsientidel võrreldes platseebot saanud patsientidega suuremat suremuse ja raskete kõrvalnähtude riski.
Interim results will be provided in the annual re-assessment reports.
Vahetulemused esitatakse iga- aastase hindamisaruande- ga.
Interim results will be provided in the CSP Annual Reports.
Vahetulemused esitatakse kliinilise järelevalveprog- rammi aastaaru- annetes
Interim Study
Uuringu
Interim Study Reports - with each PSUR
Uuringu vahearuanded – koos iga POA-ga.
Interim survival analysis
Elulemuse vaheanalüüs
Interindividual variability in systemic clearance is about 15.
Süsteemse kliirensi varieeruvus eri indiviidide vahel on umbes 15%.
Interindividual variability in the volume of distribution of parathyroid hormone is about 40.
Parathormooni jaotusruumala varieeruvus eri indiviidide vahel on umbes 40%.
Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.
Interleukiin-1 (IL-1) on põletikku reguleeriv tsütokiin, mis vahendab paljusid rakkude reaktsioone, kaasa arvatud sünoviaalse põletiku olulisi reaktsioone.
Interleukin-2 (IL-2): 3 MIU/m2/day administered by continuous intravenous infusion over 96 hours on Days 1-4 and4.5 MIU/m2/day on Days 8-11.
Interleukiin-2 (IL-2): manustamine 96 tunni jooksul intravenoosse püsiinfusioonina 1. kuni 4. päeval annuses 3 MIU/m2/ööpäevas ja 8. kuni 11. päeval annuses 4,5 MIU/m2/ööpäevas.
Interleukin-2 (IL-2, aldesleukin)
Interleukiin-2 (IL-2, aldesleukiin)
interleukin-2 (to treat cancer)
interleukiin-2 (vähi raviks)
interleukin-2 (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interleukiin-2 (vähi raviks) mittesteroidsed põletikuvastased ravimid (MSPVRid, luu- või lihasvalu leevendamiseks)
interleukin-2 (to treat cancer), adefovir dipivoxil (for HBV),
interleukiin-2 (vähi raviks), adefoviirdipivoksiil (HBV raviks),
interleukin-2 (to treat cancer).
interleukiin-2 (kasvajate raviks),
interleukin-2, also called aldesleukin (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interleukiin-2, nimetatakse ka aldesleukiiniks (vähi raviks); mittesteroidsed põletikuvastased ravimid (MSPVRid, luu- või lihasvalu leevendamiseks).
interleukin-2, also called aldesleukin (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interleukiin-2,nimetatakse ka aldesleukiiniks (vähiraviks); mittesteroidsed põletikuvastased ravimid (MSPVRid, luu- või lihasvalu leevendamiseks).
Interleukin-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T-cells and B-cells, lymphocytes, monocytes and fibroblasts, as well as malignant cells.
Interleukiin-6 on pleiotroopne põletikueelne tsütokiin, mida toodavad mitut tüüpi rakud, sh T-rakud ja B-rakud, lümfotsüüdid, monotsüüdid ja fibroblastid, aga ka maliigsed rakud.
Intermediate
Keskmine
Intermediate analysis results should be provided starting May
Analüüside vahetulemused esitada alates
INTERMEDIATE CARTON
VAHEPAKEND
INTERMEDIATE CARTON (WITHOUT BLUE BOX – COMPONENT OF MULTIPACK)
VAHEPAKEND (ILMA BLUE BOX’ITA – MULTIPAKENDI KOMPONENT)
INTERMEDIATE CARTON (WITHOUT BLUE BOX – MULTIPACK ONLY)
VAHEPAKEND (ILMA BLUE BOX’ITA – AINULT MULTIPAKEND)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) BOX OF 42 PATCHES
SISEMINE KESKMINE PAPPKARP (ILMA “BLUE BOX”) KARP 42 PLAASTRIGA
INTERMEDIATE CARTON (without Blue Box) component of a multipack - PRE-FILLED PEN
VAHEKARP (ILMA BLUE BOX'ITA) MULTIPAKENDI OSA - PEN-SÜSTEL
INTERMEDIATE CARTON (without blue box) component of a multipack – KwikPen
VAHEKARP (ilma blue box’ita), multipakendi osa - KwikPen
INTERMEDIATE CARTON (without blue box) component of a multipack – KwikPen
Väliskarp – multipakendi osa- KwikPen
INTERMEDIATE CARTON (without blue box) component of multipack- Cartridge
Väliskarp – multipakendi osa - kolbampull
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (112 TABLETS)
VAHEPAKEND (ILMA BLUE BOX’ITA) AINULT MULTIPAKENDID (112 TABLETTI)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (2X98 TABLETS)
VAHEPEALNE PAPPKARP (BLUE BOX’ITA) AINULT MULTIPAKENDID (2X98 TABLETTI)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (3x112 TABLETS)
VAHEPAKEND (ILMA BLUE BOX’ITA) AINULT MULTIPAKENDID (3x112 TABLETTI)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (56 TABLETS)
VAHEPAKEND (ILMA BLUE BOX’ITA) AINULT MULTIPAKENDID (56 TABLETTI)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (98 TABLETS)
VAHEPAKEND (ILMA BLUE BOX’ITA) AINULT MULTIPAKENDID (98 TABLETTI)
Intermediate Carton Carton 14 tablets – week 1
Karp 14 tabletti – Nädal 1
Intermediate Carton Carton 14 tablets – week 2
Karp 14 tabletti – Nädal 2
Intermediate Carton Carton 14 tablets – week 3
Karp 14 tabletti – Nädal 3
Intermediate Carton Carton 14 tablets – week 4
Karp 14 tabletti – Nädal 4
INTERMEDIATE CARTON for Multi-packs 2 packs – without blue box - 50 mg/1,000 mg film-coated tablets
VAHEKARP 2-pakendilisele multipakendile - ilma blue boxita 50 mg/1000 mg õhukese polümeerikattega tabletid
INTERMEDIATE CARTON for Multi-packs 2 packs – without blue box - 50 mg/850 mg film-coated tablets
VAHEKARP 2-pakendilisele multipakendile - ilma blue boxita 50 mg/850 mg õhukese polümeerikattega tabletid
Intermediate Carton of Multi-Pack (Without Blue Box)
Mitmikpakendi vahekarp (ilma sinise karbita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIIPAKENDI VAHEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDI SISEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDI SISEKARP („BLUE BOX“ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDI SISEKARP („BLUE BOX“’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDI VAHEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDIS SISALDUV ÜKSIKPAKEND (ILMA BLUE BOX’ita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
MULTIPAKENDI SISEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
MULTIPAKENDI VAHEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
MULTIPAKENDI VAHEPAKEND (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 10 MG
10 MG MITMIKPAKENDI SEES OLEV ÜKSIKPAKEND (ilma BLUE BOX-ita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 15 MG
15 MG MITMIKPAKENDI SEES OLEV ÜKSIKPAKEND (ilma BLUE BOX-ita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 2.5 MG
2,5 MG MITMIKPAKENDI SEES OLEV ÜKSIKPAKEND (ilma BLUE BOX-ita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 20 MG
20 MG MITMIKPAKENDI SEES OLEV ÜKSIKPAKEND (ilma BLUE BOX-ita)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) – pre-filled pen
HULGIPAKENDI VAHEKARP (ILMA BLUE BOX’ita) – pen-süstel
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) – pre-filled syringe
HULGIPAKENDI VAHEKARP (ILMA BLUE BOX’ita) - süstel
INTERMEDIATE CARTON OF MULTIPACK – WALLET (WITHOUT BLUE BOX)
HULGIPAKENDI VAHEPEALNE KARP – KUUPAKEND (ILMA SINISE KARBITA)
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX)
MULTIPAKENDITE VAHEKARP (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX)
MULTIPAKENDITE VAHEPAKEND (ILMA BLUE BOX’ITA)
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX)
MULTIPAKI SISEKARP
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
MITMIKPAKENDITE VAHEKARP (ILMA BLUE BOX’ITA), MILLES ON PA/ALU/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
MITMIKPAKENDITE VAHEPAKEND (ILMA BLUE BOX’ITA), MILLES ON PA/ALU/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
MULTIPAKENDITE VAHEKARP (ILMA BLUE BOX’ITA), MILLES ON PA/ALU/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
MULTIPAKENDITE VAHEPAKEND (ILMA BLUE BOX’ITA), MILLES ON PA/ALU/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PCTFE/PVC BLISTERS
MITMIKPAKENDITE VAHEKARP (ILMA BLUE BOX’ITA), MILLES ON PCTFE/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PCTFE/PVC BLISTERS
MULTIPAKENDITE VAHEKARP (ILMA BLUE BOX’ITA), MILLES ON PCTFE/PVC BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PVC/PCTFE BLISTERS
MITMIKPAKENDITE VAHEPAKEND (ILMA BLUE BOX’ITA), MILLES ON PVC/PCTFE BLISTRID
INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING PVC/PCTFE BLISTERS
MULTIPAKENDITE VAHEPAKEND (ILMA BLUE BOX’ITA), MILLES ON PVC/PCTFE BLISTRID
INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS)
360 MULTIPAKI VAHETU KARP (4 PAKKI 90 x 1 TABLETTI) – ILMA BLUE BOX’ITA /
INTERMEDIATE CARTON WITHIN MULIPACK (4 PRE-FILLED PENS) (WITHOUT BLUE BOX)
MITMIKPAKENDIS SISALDUV VAHEPAKEND (4 PEN-SÜSTLIT) (ILMA BLUEBOX’ITA)
INTERMEDIATE CARTON WITHIN MULIPACK (4 PRE-FILLED SYRINGES) (WITHOUT BLUE BOX)
MITMIKPAKENDIS SISALDUV VAHEPAKEND (4 SÜSTLIT) (ILMA BLUEBOX’ITA)
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS)
MULTIPAKENDI VAHEKARP (3 PAKENDIT 56 ÕHUKESE POLÜMEERIKATTEGA TABLETIGA)
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUE BOX)
MULTIPAKENDI VAHEKARP (3 PAKENDIT 56 ÕHUKESE POLÜMEERIKATTEGA TABLETIGA) (ILMA BLUE BOX’ita)
Intermediate carton within Multipack of 10 (for 2 pre-filled pens and 2 alcohol wipes) (without bluebox)
Mitmikpakendis (10) sisalduv vahepakend (2 pen-süstlit ja 2 alkoholiga niisutatud lapikest) (ilma sinise raamita)
Intermediate carton within Multipack of 10 (for 2 pre-filled syringes and 2 alcohol wipes) (without bluebox)
Mitmikpakendis (10) sisalduv vahepakend (2 süstlit ja 2 alkoholiga niisutatud lapikest) (ilma sinise raamita)
Intermediate carton within Multipack of 6 (for 2 pre-filled pens and 2 alcohol wipes) (without blue box)
Mitmikpakendis (6) sisalduv vahepakend (2 pen-süstlit ja 2 alkoholiga niisutatud lapikest) (ilma sinise raamita)
Intermediate carton within Multipack of 6 (for 2 pre-filled syringes and 2 alcohol wipes) (without bluebox)
Mitmikpakendis (6) sisalduv vahepakend (2 süstlit ja 2 alkoholiga niisutatud lapikest) (ilma sinise raamita)
INTERMEDIATE CHILD-RESISTANT BLISTER (Single dose)
LASTEKINDEL VAHEPEALNE BLISTERPAKEND (üheannuseline)
INTERMEDIATE CHILD-RESISTANT BLISTER PACK (Single dose)
LASTEKINDEL VAHEPEALNE BLISTERPAKEND (üheannuseline)
Intermediate metabolism: CYP2C19*1/*2 or *1/*3
Keskmine metabolism: CYP2C19*1/*2 või *1/*3
Intermediate metabolism: CYP2C19*1/*2 or *1/*3 26
Keskmine metabolism: CYP2C19*1/*2 või 26
INTERMEDIATE PACKAGING - WALLET CARD (WITHOUT BLUE BOX)
VAHEPAKEND – TASKU KAART (ILMA SINISE KARBITA)
Intermediate packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue box
Üks sisepakendi karp sisaldab 100 tabletti, kokku on karbis 200 (2 x 100) tabletti, ilma blue box’ita
Intermediate packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue box
Üks sisepakendi karp sisaldab 100 tabletti, kokku on pakendis 200 (2 x 100) tabletti, ilma blue box’ita
Intermediate packaging containing 100 tablets for multipack of 200 (2 x 100) tablets [without Blue Box]
Üks sisepakendi karp sisaldab 100 tabletti, kokku on hulgipakendis 200 (2 x 100) tabletti [ILMA BLUE BOX’ITA]
Intermediate packaging containing 100 tablets for multipack of 200 (2 x 100) tablets [without Blue Box]
Üks sisepakendi karp sisaldab 100 tabletti, kokku on hulgipakendist 200 (2 x 100) tabletti [ILMA BLUE BOX’ITA]
Intermediate packaging containing 100 tablets for multipack of 200(2 x 100) tablets [without Blue Box]
Üks sisepakendi karp sisaldab 100 tabletti, kokku on hulgipakendist 200 (2 x 100) tabletti [ILMA BLUE BOX’ITA]
Intermediate packaging containing 100tablets for multipack of 200(2 x 100) tablets [without Blue Box]
Üks sisepakendi karp sisaldab 100 tabletti, kokku on hulgipakendist 200 (2 x 100) tabletti [ILMA BLUE BOX’ITA]
INTERMEDIATE PACKAGING FOR SINGLE BLISTER:SLEEVE
ÜHEANNUSELISE BLISTERPAKENDI VAHEPAKEND: VUTLAR
INTERMEDIATE WALLET OF MULTIPACK (WITHOUT BLUE BOX) INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
HULGIPAKENDIS SISALDUV KOKKUVOLDITAV SISEKARP (ILMA BLUE BOX’ita) HULGIPAKENDIS SISALDUV ÜKSIKPAKEND (ILMA BLUE BOX’ita)
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Vahelduva allergilise riniidi (sümptomid esinevad vähem kui 4 päeva nädalas või vähem kui 4 nädalat) puhul tuleb ravi määramisel lähtuda patsiendi haiguse ajaloost ning ravi võiks katkestada sümptomite lahenemise korral ning taasalustada nende ilmnemisel.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Vahelduva allergilise riniidi (sümptomid esinevad vähem kui 4 päeva nädalas või vähem kui 4nädalat) puhul tuleb ravi määramisel lähtuda patsiendi haiguse ajaloost ning ravi võiks katkestada sümptomite lahenemise korral ning taasalustada nende ilmnemisel.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Vahelduva allergilise riniidi korral (esinevad sümptomid vähem kui 4 päeva nädalas või vähem kui 4 nädalat) tuleb ravi määramisel lähtuda patsiendi anamneesist ning ravi võib katkestada sümptomite kadumisel ning taasalustada nende ilmnemisel.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Vahelduva allergilise riniidi korral (sümptomid esinevad vähem kui 4 päeva nädalas või vähem kui 4 nädalat) tuleb ravi määramisel lähtuda patsiendi anamneesist ning ravi võib katkestada sümptomite kadumisel ning taasalustada nende ilmnemisel.
Intermittent explosive disorder
Vahelduv ähvardav käitumishäire
Intermittent vomiting and soft faeces were observed in dogs after repeated oral administration of
Pärast korduvate suukaudsete 2,7 kordsete maksimumdooside manustamise järgselt täheldati koertel vahelduvat oksendamist ja pehmeid väljaheiteid.
Internal analytical precision must be less than + 0.3 ‰ 13C for 20 replicate analyses of the same reference gas sample and remain within 23SD’s of the mean for breath analyses.
Sisemine analüütiline täpsus peab olema vähem kui ±0.3‰ 13C sama referentsgaasi 20 proovi analüüsi kohta ning jääma 3 standardhälbe piiridesse keskmisest väljahingatud õhu proovide jaoks.
Internal analytical precision must be less than + 0.3 ‰ 13C for 20 replicate analyses of the same reference gas sample and remain within 3SD’s of the mean for breath analyses.
Sisemine analüütiline täpsus peab olema vähem kui ±0.3‰ 13C sama referentsgaasi 20 proovi analüüsi kohta ning jääma 3 standardhälbe piiridesse keskmisest väljahingatud õhu proovide jaoks.
internal bleeding (rare) bleeding into joints causing painful swelling (rare)
isemine verejooks (harv); verejooks liigestesse, mis põhjustab valulikku turset (harv).
internal bleeding in the abdomen (retroperitoneal bleeding) bleeding in the brain (cerebral haemorrhage).
isemine verejooks kõhus (retroperitoneaalne verejooks) peaaju verejooks (tserebraalne hemorraagia).
internal bleeding in the brain or abdomen
kolju- või kõhuõõnesisene verejooks
internal bleeding in the brain, liver or abdomen
maksaverejooks, kolju- või kõhuõõnesisene verejooks
Internalisation and release of the toxin into the cytosol of the nerve terminals
Toksiini sisenemine närvilõpmete tsütosooli